Lindenhofgruppe Geschäftsbericht 2018

Thema Fachgebiet Ansprechperson Lindenhofgruppe Kooperations- partner / Sponsor A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (TRANSPORT) Pneumologie Dr. med. Reta Fischer Biner Vertex Pharma- ceuticals A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Longterm Treatment With V X-661 in Combi- nation With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation Pneumologie Dr. med. Reta Fischer Biner Vertex Pharma- ceuticals A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of V X-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Hetero- zygous for the F508del Mutation and a Minimal Function Mutation (F/MF) Pneumologie Dr. med. Reta Fischer Biner Vertex Pharma- ceuticals A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of V X-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation Pneumologie Dr. med. Reta Fischer Biner Vertex Pharma- ceuticals Registrierstudie beim Prostatakarzinom: «Swiss Prostate Brachytherapy Registry». Radio-Onkologie Dr. med. Armin Thöni Kantonsspital St. Gallen Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients. A randomized, double-blinded, placebo-controlled, phase III trial (SAKK 41/13). Viszeralchirurgie Prof. Dr. med. Markus Borner Schweizerische Arbeitsgemein- schaft für Klini- sche Krebsfor- schung Geschäftsbericht 2018 84 Lehre und Forschung